. Participants of Study, RIA Screening, and more caplets at noon. According to the label, each caplet Ephedrine Quantitation contained 12 mg of"ephedra group alkaloids." Independent
Meth.
analysis by gas chromatography-mass spectrometry (GC-MS) RIA FquivalenB Ephedrine confirmed the amount of ephedrine per caplet. Urine specimens Subject Gender Wt (Ibs) Dose* screen (ng/mL) (ng/mt) were collected early morning, immediately before the first daily dose. A second urine specimen was collected 4 h after the first Quantitative analyses were performed on a Hewlett-Packard 5995 GC-MS equipped with an HP-Ultra 2 (19091B-012) capillary column (25 m x 0.32-ram i.d., 0.17-prn film thickness). The MS was operated in the SIM mode monitoring the 58 and 61 ions for ephedrine-do and ephedrine-d3, respectively. The 44 and 91 ions were also monitored to screen for amphetamine and methamphetarnine.
Vital signs were not monitored during the studies, and there were no significant medical complaints, although Subject 2 reported being "jittery" after the second dose on the first day and "neck stiffness" during the second day. Even with these side reactions, Subject 2 continued with the five-day protocol, as did all the other participants.
Following the completion of the dosing regimen, the urine specimens, which were collected 4 h after the last dose on the last day for each subject, were screened for methamphetamine by RIA at the 1000-ng/rnL cutoff. Three of the five subjects had positive screening test results for methamphetamine, when in fact, no metharnphetamine had been taken. The GC-MS analyses were negative for amphetamine and methamphetarnine in all of the positive RIA urine specimens.
The extent of cross-reactivity of ephedrine to the methamphetarnine antibody in each of the specimens was determined and reported as methamphetamine equivalents. The concentration of ephedrine in each of the urines was determined by GC-MS. All of the urine specimens for Subject 5 were screened for methamphetamine, and, in addition, those urines close to the positive cutoff value were analyzed for ephedrine content. Table  II summarizes the results.
The manufacturer of Metabolife 356 recommends using 1-2 caplets 2-3 times daily, not exceeding 8 caplets per day. Subject 1, taking one caplet twice a day, had a final urine ephedrine concentration of approximately 8000 ng/mL, whereas Subject 3, taking two caplets twice daily, had a final concentration of greater than 120,000 ng/mL. Urine ephedrine concentrations of approximately 40,000 ng/mL (approximately 1000 ng/mL methamphetamine equivalents) are sufficient to produce a positive RIA screen.
There were striking differences in ephedrine concentrations between subjects on the same dosage regimen. Humans do not metabolize ephedrine to any significant degree (1), suggesting that the observed differences in ephedrine concentrations have nothing to do with genetic polymorphism, but rather are a reflection of each individual's states of hydration/dehydration or urinary pH. Excretion is faster in an acidic urine than in an alkaline urine. Unregulated workplace testing programs, and even hospital emergency rooms, rely on unconfirmed immunoassays, which are often incorporated into point-of-care testing devices and leave no audit trail. There is a very real possibility that innocent herbal product users may be falsely accused of drug abuse.
Results with the immunoassay tested here may or may not be similar to results achieved with other immunoassy kits. In the absence of specific tests, there is no way to know. Pre-market studies of immunoassay cross-reactivity are almost always done with spiked urine samples. Though the concentrations used for such testing may seem high (100,000 ng/mL or even higher), the results of our study suggest that they may not be high enough and do not predict results in clinical practice.
Consumption of less than 50 mg of ephedra alkaloids per day by an individual with unnoticed mild dehydration (Subject 3, who had no medical complaints and who continued to work throughout the study) resulted in urine concentrations of > 100,000 ng/mL. This observation suggests that false-positive screening test results, especially by DPC methamphetamine assays following use of ephedra alkaloids including Metabolife 356, may be more common than had previously been appreciated. 
